Minerva endocrinology最新文献_第7页

Semaglutide and obesity: beyond the nutritional and lifestyle intervention? 塞马鲁肽与肥胖症：营养和生活方式干预之外？

IF 2.5

Minerva endocrinology Pub Date : 2024-06-01 DOI: 10.23736/S2724-6507.23.04103-9

Livia Basile, Rossella Cannarella, Stefano Iuliano, Aldo E Calogero, Rosita A Condorelli, Emanuela A Greco, Antonio Aversa, Sandro LA Vignera

{"title":"Semaglutide and obesity: beyond the nutritional and lifestyle intervention?","authors":"Livia Basile, Rossella Cannarella, Stefano Iuliano, Aldo E Calogero, Rosita A Condorelli, Emanuela A Greco, Antonio Aversa, Sandro LA Vignera","doi":"10.23736/S2724-6507.23.04103-9","DOIUrl":"https://doi.org/10.23736/S2724-6507.23.04103-9","url":null,"abstract":"Semaglutide is the second marketed glucagon-like peptide 1 receptor agonist that can be used safely and efficiently in non-diabetic people with excess weight, providing a new milestone in the pharmacological treatment of obesity. This narrative review aims to describe the clinical actions of this new drug in weight management in non-diabetic patients along with possible side-effects and dropout reasons. To accomplish this, the PubMed database was searched to retrieve the most relevant clinical studies published to date on this topic, using the following keywords \"semaglutide and obesity\". Currently, semaglutide is on the market in two formulations, the once-weekly subcutaneous (s.c.) semaglutide and once-daily oral semaglutide. Data in the literature on the anti-obesity action of semaglutide are available for both routes of administration of the drug, with a prevalence of studies using the s.c. one. However, given its dosage, oral semaglutide may provide greater attractiveness and better treatment adherence, but further research is needed in this field.","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":"49 2","pages":"182-195"},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141723938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacological treatment of non-responders following bariatric surgery. 减肥手术后无应答者的药物治疗：现有证据综述。

IF 2.5

Minerva endocrinology Pub Date : 2024-06-01 Epub Date: 2021-04-01 DOI: 10.23736/S2724-6507.21.03311-3

Federica Vinciguerra, Luana M Romeo, Lucia Frittitta, Roberto Baratta

{"title":"Pharmacological treatment of non-responders following bariatric surgery.","authors":"Federica Vinciguerra, Luana M Romeo, Lucia Frittitta, Roberto Baratta","doi":"10.23736/S2724-6507.21.03311-3","DOIUrl":"10.23736/S2724-6507.21.03311-3","url":null,"abstract":"Obesity is a complex chronic disease and requires a long-term multidisciplinary management. Even patients undergoing bariatric surgery, one the most effective treatments for obesity, can have insufficient weight loss (IWL) than expected (primary non responder) or weight regain (WR) after a successful primary procedure (secondary non responder). A poor response represents a challenge of bariatric surgery that can induce persistence or recurrence of obesity-related comorbidities, prejudicing benefits of surgery. Increasing evidence suggests that weight loss medications represent a useful strategy in obesity care also after bariatric surgery procedures. This narrative review summarizes the evidence concerning anti-obesity therapy in the management of no-responders to primary bariatric surgery. Available data on liraglutide (one randomized double-blind placebo-controlled trial, three prospective and three retrospective studies), naltrexone/bupropion (three retrospective studies), orlistat (one case control prospective and one retrospective studies) and topiramate and phentermine (five retrospective studies) have been considered. Available data suggest that weight loss medications could offer a significant adjunctive benefit to lifestyle and behavioral modifications in the life-long management of obesity. Newer treatment modalities including the use of anti-obesity drugs provide patients and healthcare providers with more options in the management of poor response after bariatric surgery.","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":"196-204"},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25537265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The mTOR-inhibitor everolimus reduces hypervolemia in patients with primary aldosteronism. mTOR抑制剂依维莫司可降低原发性醛固酮增多症患者的高血容量。

IF 2.5

Minerva endocrinology Pub Date : 2024-06-01 Epub Date: 2021-04-01 DOI: 10.23736/S2724-6507.21.03382-0

Beckey Trinh, Thilo Burkard

{"title":"The mTOR-inhibitor everolimus reduces hypervolemia in patients with primary aldosteronism.","authors":"Beckey Trinh, Thilo Burkard","doi":"10.23736/S2724-6507.21.03382-0","DOIUrl":"10.23736/S2724-6507.21.03382-0","url":null,"abstract":"Background: We recently showed in a proof-of-concept study that treating individuals with primary aldosteronism with the mTOR-inhibitor everolimus decreases home blood pressure and renin suppression overall, and markedly reduces aldosterone levels in a subset of individuals. Based on these findings, the question arose whether the effects of everolimus were also mediated via aldosterone-independent mechanisms. Here, we undertook an exploratory, secondary analysis of above-mentioned study to comprehensively investigate how everolimus impacted the hemodynamic status of the study participants, which in turn could elucidate these mechanisms.Methods: Hemodynamic parameters were measured in study participants with primary aldosteronism at baseline, after treatment with everolimus 0.75 mg orally twice daily for 2 weeks and after a 2-week wash-out. Of the 14 participants, 10 participants had complete data sets for peripheral and central blood pressure, heart rate and pulse wave velocity, and 7 participants had complete data sets for cardiac index, inotropic state index, left stroke work index and stroke systemic vascular resistance index that could be analyzed. Parameters were acquired by brachial oscillometry (Mobil-o-graph PWA) and thoracic electrical bioimpedance (HOTMAN® System).Results: After treatment with everolimus, peripheral (P=0.049) and central (P=0.037) diastolic blood pressure, as well as hypervolemia (P=0.008) were significantly decreased. Likewise, peripheral (P=0.073) and central systolic blood pressure (P=0.166) trended downwards.Conclusions: Everolimus lowers central and peripheral blood pressure in individuals with primary aldosteronism, possibly by decreasing primary aldosteronism-induced hypervolemia and preload.","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":"150-157"},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25537225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Autosomal dominant pseudohypoparathyroidism type 1b due to STX16 deletion: a case presentation and literature review. STX16缺失导致的常染色体显性假性甲状旁腺功能减退症1B型：一个病例和文献综述。

IF 2.5

Minerva endocrinology Pub Date : 2024-06-01 Epub Date: 2022-02-04 DOI: 10.23736/S2724-6507.20.03233-2

Georgios Kostopoulos, Georgios Tzikos, Alexandros Sortsis, Konstantinos Toulis

{"title":"Autosomal dominant pseudohypoparathyroidism type 1b due to STX16 deletion: a case presentation and literature review.","authors":"Georgios Kostopoulos, Georgios Tzikos, Alexandros Sortsis, Konstantinos Toulis","doi":"10.23736/S2724-6507.20.03233-2","DOIUrl":"10.23736/S2724-6507.20.03233-2","url":null,"abstract":"Introduction: Pseudohypoparathyroidism (PHP) is a heterogeneous group of rare, genetically related, endocrine disorders, characterized by end-organ resistance to parathyroid hormone (PTH) action and other G protein-coupled receptors (GPCRs) related hormones. The clinical variants of PHP are classified according to the presence of features of Albright's hereditary osteodystrophy (AHO) and in vivo response to exogenous PTH. Autosomal dominant PHP1b is often caused by a deletion in the syntaxin-16 (STX16) gene, leading to a loss of methylation in the A/B exon of the guanine nucleotide-binding protein a-stimulating polypeptide (GNAS) complex. Herein, we present a case of a 41-year-old man with familiar PHP1b due to a maternal inherited 3-kb STX16 deletion, who was referred to us for consultation by artificial reproductive technology specialists.Evidence acquisition: A bibliographic search was performed in electronic databases (PubMed and Cochrane Library) to identify similar cases.Evidence synthesis: Twenty studies (case-series or reports) were eligible. These studies included collectively 120 patients; 46 patients (38.3%) presented with symptoms of hypocalcemia; 38 were asymptomatic (31.7%); data for 36 patients (30%) were unavailable. Thyroid-stimulating hormone (TSH) resistance was documented in 25 occasions (21%); growth hormone deficiency in 2 (1.7%); 3 patients shared features of the AHO (2.5%); 6 had abnormal bone mineral density test (5%). Notable is the development of tertiary hyperparathyroidism in 3 individuals (2.5%).Conclusions: The present review confirms the heterogeneity in the clinical spectrum of familiar PHP1b. Future research should focus on the molecular characterization of the GNAS disorders, leading to a facile diagnosis and appropriate genetic counseling.","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":"217-225"},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39750963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A comparison of intensive insulin therapy and dipeptidyl peptidase-4 inhibitor plus metformin combination in newly diagnosed type 2 diabetes mellitus. 对新诊断的 2 型糖尿病患者进行胰岛素强化治疗与二肽基肽酶-4 抑制剂加二甲双胍联合疗法的比较。

IF 2.5

Minerva endocrinology Pub Date : 2024-06-01 Epub Date: 2023-05-09 DOI: 10.23736/S2724-6507.23.03928-3

Halit Diri, Basak Bolayir, Hikmet Soylu, Sedat Cetin, Mehmet Simsek

引用次数: 0

Risk of erythrocytosis in transgender individuals undergoing testosterone therapy: a systematic review. 接受睾酮治疗的变性人患红细胞增多症的风险：系统综述。

IF 2.5

Minerva endocrinology Pub Date : 2024-06-01 DOI: 10.23736/S2724-6507.24.04171-X

Alberto Scala, Andrea Graziani, Fabrizio Vianello, Alberto Ferlin, Andrea Garolla

{"title":"Risk of erythrocytosis in transgender individuals undergoing testosterone therapy: a systematic review.","authors":"Alberto Scala, Andrea Graziani, Fabrizio Vianello, Alberto Ferlin, Andrea Garolla","doi":"10.23736/S2724-6507.24.04171-X","DOIUrl":"https://doi.org/10.23736/S2724-6507.24.04171-X","url":null,"abstract":"Introduction: In transgender individuals assigned female at birth, testosterone therapy is employed for body masculinization. Guidelines recommend close monitoring for potential side effects of hormonal therapy, especially during the first year. Erythrocytosis is a common finding during testosterone therapy and has been associated with a potential risk of thrombotic and cardiovascular events. Currently, the hematologic effects of testosterone therapy are understudied, with existing data primarily derived from the cisgender male population. The aim of this study was to comprehensively examine the hematological changes induced by testosterone therapy in the transgender population.Evidence acquisition: A systematic search was conducted using the electronic database PubMed.Evidence synthesis: Thirty-six manuscripts were retrieved. After screening for original studies, 19 articles were included. Selected articles were published between 2005 and 2023.Conclusions: In our systematic review, the prevalence of erythrocytosis varied from 0% to 29.3%, with severe erythrocytosis ranging from 0.5% to 2.3%. Testosterone therapy was associated with an increase in hemoglobin and hematocrit, particularly within the first year of therapy. Factors such as serum testosterone levels, along with the duration, doses, and formulation of testosterone therapy, were found to be associated with the development of erythrocytosis. Further research is crucial to provide specific recommendations for clinical practice.","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":"49 2","pages":"205-216"},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141723937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Highlights of the April-June 2024 issue. 2024 年 4-6 月刊的重点内容。

IF 2.5

Minerva endocrinology Pub Date : 2024-06-01 DOI: 10.23736/S2724-6507.24.04238-6

Giovanni Vitale

引用次数: 0

Quality of outcome reporting for clinical trails on medullary thyroid cancer registered on ClinicalTrials.gov. 在 ClinicalTrials.gov 上注册的甲状腺髓样癌临床试验结果报告的质量。

IF 2.5

Minerva endocrinology Pub Date : 2024-06-01 Epub Date: 2023-05-09 DOI: 10.23736/S2724-6507.23.04034-4

Giuseppe Fanciulli, Stefania Bellino, Anna LA Salvia

引用次数: 0

Effectiveness and safety of lenvatinib in a series of advanced well-differentiated thyroid carcinomas from a single tertiary cancer center and literature review. 来伐替尼对来自一家三级癌症中心的一系列晚期分化良好甲状腺癌的有效性和安全性以及文献综述。

IF 4.1

Minerva endocrinology Pub Date : 2024-03-21 DOI: 10.23736/S2724-6507.23.03982-9

Inês L Damásio, Ana Figueiredo, Joana Maciel, Mariana Horta, Tiago N Silva, Joana Simões-Pereira, Sara Donato, Valeriano Leite

{"title":"Effectiveness and safety of lenvatinib in a series of advanced well-differentiated thyroid carcinomas from a single tertiary cancer center and literature review.","authors":"Inês L Damásio, Ana Figueiredo, Joana Maciel, Mariana Horta, Tiago N Silva, Joana Simões-Pereira, Sara Donato, Valeriano Leite","doi":"10.23736/S2724-6507.23.03982-9","DOIUrl":"https://doi.org/10.23736/S2724-6507.23.03982-9","url":null,"abstract":"Background: Treatment of advanced differentiated thyroid carcinoma (DTC) remains a challenge as 25-50% of patients with locally invasive or distant metastatic disease become refractory to radioiodine (RAI) therapy. Tyrosine kinase inhibitors (TKI) are increasingly used in this setting. The SELECT trial demonstrated that lenvatinib, a multikinase inhibitor, significantly improved progression free survival (PFS) compared to placebo. Our aim was to report the effectiveness and safety of lenvatinib in our series of patients with advanced DTC.Methods: A total of 25 patients with advanced DTC followed at a single tertiary center from January of 2016 to January of 2022 were retrospectively reviewed.Results: Patients were treated with a mean daily dose of lenvatinib of 16.9 mg for a mean of 9.1 months. Median estimated PFS was 31.3 months. One patient achieved complete response. The objective response rate (ORR) was 40% and the disease control rate was 84%. The mean change in summed longest diameter of target lesions from baseline to nadir was -36.9%. Lenvatinib prolonged the tumor volume doubling time in 86.7% patients. Interestingly, we found that patients treated with a lower dose of lenvatinib (<16.9 mg daily) had a significantly higher PFS and ORR than patients treated with higher dosages (>16.9 mg). Adverse events were frequently reported.Conclusions: Our results confirm the effectiveness of lenvatinib in the management of patients with advanced DTC and support the need to adjust the dosage of lenvatinib to patient´s performance status and comorbidities.","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140184907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Leptin effects: focusing on the relationship between obesity and male infertility. 瘦素效应：关注肥胖与男性不育之间的关系。

IF 4.1

Minerva endocrinology Pub Date : 2024-03-01 Epub Date: 2022-10-17 DOI: 10.23736/S2724-6507.22.03901-X

Davide LA Padula, Lucia Zavaglia, Tarig Hamad, Marta C Nocito, Saveria Aquila, Paola Avena, Vittoria Rago

引用次数: 0